Bispecific Antibodies and Other Non-CAR Targeted Therapies and HSCT: Decreased Toxicity for Better Transplant Outcome in Paediatric ALL?

Kállay, Krisztián Miklós; Algeri, Mattia; Buechner, Jochen; Krauss, Aviva C

Kállay, Krisztián Miklós; Algeri, Mattia; Buechner, Jochen; Krauss, Aviva C.

Afiliação

Kállay KM; Pediatric Hematology and Stem Cell Transplantation Department, National Institute of Hematology and Infectious Diseases, Central Hospital of Southern Pest, Budapest, Hungary.
Algeri M; Department of Pediatric Hematology and Oncology, Scientific Institute for Research and Healthcare (IRCCS), Bambino Gesù Childrens' Hospital, Rome, Italy.
Buechner J; Department of Pediatric Hematology and Oncology, Oslo University Hospital, Oslo, Norway.
Krauss AC; Division of Hematopoietic Stem Cell Transplantation, Department of Hematology-Oncology, Schneider Children's Medical Center of Israel, Petach Tikvah, Israel.

Front Pediatr ; 9: 795833, 2021.

Article em En | MEDLINE | ID: mdl-35252074

Palavras-chave

Trisomy 21 (down syndrome); blinatumomab; haematopoietic stem cell transplantation (HSCT); infant ALL; inotuzumab; paediatric acute lymphoblastic leukaemia (ALL)

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Risk_factors_studies Idioma: En Revista: Front Pediatr Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Hungria

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google